Innov Clin Neurosci. 2026;23(1–3):32–38. by Humphrey Masimba Makumbirofa, MSc; Tariro Tsitsidzashe Hluyo, BPharm; Jonathan Chaweza, BTech; Simbarashe Wandayi, MVPG, BVSc; and Nyarai Desiree Soko, PhD, MSc Messrs. Makumbirofa, Hluyo, Chaweza,
Innov Clin Neurosci. 2026;23(1–3):39–46. by Steven Wickens, MPsych, and Trevor Brown, PhD Both authors are with Neurocare Group, Melbourne, Australia. FUNDING: No funding was provided for this article. DISCLOSURES: The
Innov Clin Neurosci. 2026;23(1–3):47–53. by Hamed Zarei, MD*; Mohammadhossein Vazirizadeh-Mahabadi, MD*; Narges Saadatipour, MD; Maryam Pazhooha, MD; Mostafa Hosseini, PhD; and Mahmoud Yousefifard, PhD *Drs. Zarei and Vazirizadeh-Mahabadi contributed equally
by Justin Pope, JD Mr. Pope is Associate Director of Risk Management at Professional Risk Management Services (PRMS). FUNDING: No funding was provided for the preparation of this article. DISCLOSURES:
